Xintian Qin

发表

Efficacy and safety of KL-A167 in previously treated recurrent or metastatic nasopharyngeal carcinoma: a multicenter, single-arm, phase 2 study

W. Wang, Jinsheng Hong, Liangfang Shen, 2022, The Lancet regional health. Western Pacific.

Ef ﬁ cacy and safety of KL-A167 in previously treated recurrent or metastatic nasopharyngeal carcinoma: A multicenter, single-arm, phase 2 study

R. Guo, Jiong Cai, S. Qiu, 2022 .

LncRNA TSIX acts as a ceRNA of miR-342-3p to Promote the Progression of Nasopharyngeal Carcinoma by Regulating AGR2

Dan-dan Wang, Shu-peng Chen, Zhe Wang, 2020 .

Detection of nasopharyngeal carcinoma susceptibility with single nucleotide polymorphism analysis using next-generation sequencing technology

Fan Yang, Xicheng Wang, Shujing Huang, 2017, Oncotarget.

Investigation of Hippo pathway-related prognostic lncRNAs and molecular subtypes in liver hepatocellular carcinoma

Baoqiu Liu, Wan-li Xiao, Xintian Qin, 2023, Scientific Reports.

Detection of nasopharyngeal carcinoma susceptibility with single nucleotide polymorphism analysis using next-generation sequencing technology

Fan Yang, Xicheng Wang, Dongchen Liu, 2017, Oncotarget.

The efficacy and safety of taletrectinib in patients with TKI-naïve or crizotinib-pretreated ROS1-positive non–small cell lung cancer (NSCLC).

Yunpeng Liu, N. Yang, M. Tao, 2022, Journal of Clinical Oncology.

Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trial

Ying Cheng, Yanqiu Zhao, N. Yang, 2023, Signal transduction and targeted therapy.

Taletrectinib (AB-106; DS-6051b) in metastatic non-small cell lung cancer (NSCLC) patients with ROS1 fusion: Preliminary results of TRUST.

N. Yang, M. Tao, Caicun Zhou, 2021 .

Efficacy and safety of cadonilimab in previously treated recurrent or metastatic nasopharyngeal carcinoma(COMPASSION-06): A phase II multicenter study.

H. Mai, Baiyong Li, Shanshan Guo, 2024, Oral oncology.